KUALA LUMPUR, Duopharma Biotech Bhd has announced the appointment of Wan Amir-Jeffery Wan Abdul Majid as its new group chief executive officer (Group CEO), effective Oct 1, 2025.
The company’s chairman, Datin Paduka Kartini Abdul Manaf, said Wan Amir-Jeffery’s leadership journey within Duopharma has been marked by significant contributions at both strategic and operational levels.
“I am confident that under his stewardship, Duopharma Biotech will maintain its healthy growth momentum and further strengthen its position as one of Malaysia’s leading pharmaceutical players,” she said in a statement today.
Wan Amir-Jeffery brings with him nearly a decade of experience with Duopharma Biotech, having joined the group in September 2016 as chief strategy officer. He steadily rose through the ranks—becoming chief operating officer in 2018, chief commercial officer in 2020, CEO of Commercial in 2022, and CEO of Group Operations in 2024—before taking on the group’s top leadership role.
Academically, he holds a Bachelor of Business Administration in International Trade from the University of Central Arkansas, United States, and is an alumnus of the Senior Management Development Program at Harvard Business School, underscoring his strong foundation in global business leadership.
Beyond his corporate role, Wan Amir-Jeffery is also active in industry leadership. He currently serves as a vice president of the Malaysian Organisation of Pharmaceutical Industries (MOPI) for the 2025–2027 term, reflecting his wider influence in shaping the pharmaceutical sector in Malaysia.
The appointment signals Duopharma Biotech’s commitment to sustained growth and innovation as the company continues to navigate an increasingly competitive healthcare landscape, both domestically and in the region.
